REVEAL GENOMICS AND ONA THERAPEUTICS JOIN FORCES TO ADVANCE NEXT-GENERATION CANCER TREATMENT

Redefining precision oncology

Unlocking the full potential of patient information

[data-wf-bgvideo-fallback-img] { display: none; } @media (prefers-reduced-motion: reduce) { [data-wf-bgvideo-fallback-img] { position: absolute; z-index: -100; display: inline-block; height: 100%; width: 100%; object-fit: cover; } }

We want to change how biomarkers are routinely used in oncology

Analyze
the Past

Analyzing
complex genomic
and clinical data

Decode
the present

Decoding biomarkers before,
during or after therapies
using different biopsy-based approaches

Reveal
the future

Revealing innovative tests of
high analytical complexity,
but easy-to-interpret results

Learn more

The first genomic tool for patients with
HER2+ breast cancer

HER2DX^® is intended to help select the optimal treatment strategy for patients.

REVEAL GENOMICS^®and HER2DX^®are registered trademarks of REVEAL GENOMICS S.L.

Learn More Order HER2DX^®

New

REPORT

Updated version with the most recent studies conducted on HER2DX^®.

More visual results, the scores are shown in representation with their scale.

Extensive description and guidance for reading the results, their clinical significance and supporting data.

Extensive explanation
of the scores for a better interpretation of the results.

DOWNLOAD A SAMPLE REPORT

PRESS RELEASE

REVEAL GENOMICS AND ONA THERAPEUTICS JOIN FORCES TO ADVANCE NEXT-GENERATION CANCER TREATMENT

NEWS

Genomic assay changes minds on HER2+ BC treatment

BLOG

We continue to gather more support data for HER2DX®